Antihypertensive drugs

Specific and irreversible inhibitor of serine proteases. Inhibits chymotrypsin, kallikrein, plasmin, thrombin, trypsin and other related thrombolytic enzymes. Less toxic substitute for PMSF.

Specific and irreversible inhibitor of serine proteases. Inhibits chymotrypsin, kallikrein, plasmin, thrombin, trypsin and other related thrombolytic enzymes. Less toxic substitute for PMSF.

https://www.inorganicventures.com/coa-sds-search

https://www.inorganicventures.com/coa-sds-search

An inhibitor of EGFR and VEGFR tyrosine kinases (IC₅₀s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively) demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models.

An inhibitor of EGFR and VEGFR tyrosine kinases (IC₅₀s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively) demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models.

An inhibitor of EGFR and VEGFR tyrosine kinases (IC₅₀s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively) demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models.

An inhibitor of EGFR and VEGFR tyrosine kinases (IC₅₀s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively) demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models.

https://www.inorganicventures.com/coa-sds-search

https://www.inorganicventures.com/coa-sds-search

https://www.inorganicventures.com/coa-sds-search

https://www.inorganicventures.com/coa-sds-search